Answers are grounded in this paper and cite their sources.
Critique of arguments on baclofen use in alcohol use disorders, suggesting ethical support for off-label medication.
High diffusion of the use of baclofen in patients with alcohol use disorders (AUD) in India has raised concerns from Braillon and Naudet. They say the practice is based on poor evidence and ignores possible harms to patients. This article critiques their arguments and makes a reasoned, ethical, and evidence-informed case for baclofen as a treatment option for AUD, albeit a second-line one, especially because of issues with acceptability and cost of other approved pharmacotherapies.
No takes yet. Share an insight, caveat, or question.
Dheeraj Kattula (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: